NDOGENOUS proteases are involved in a wide variety of physiological functions and several have been implicated in contributing to pathological states as well. Much interest has developed in the potential role of the cytoplasmic, calcium-dependent cysteine protease, calpain, in cerebral ischemia. 3, 6, 31, 36, 37 Calpain within neurons is activated by calcium influx after the onset of cerebral ischemia and is linked to the early breakdown of cytoskeletal components. 27, 33, 39 Leupeptin is a protease inhibitor that reduces the activity of calpain as well as other cysteine proteases such as cathepsins B, L, H, and S. Intraventricular infusion of leupeptin was found to decrease the extent of ischemic cell damage in an animal model of global cerebral ischemia.
halothane in a 2:1 N 2 O/O 2 mixture using a face mask. Body temperature was maintained at a constant temperature of 37°C by means of a recirculating heating pad with an intrarectal thermocouple. A ventral neck incision was made and the right carotid bifurcation was isolated using a microsurgical technique. The external carotid artery was ligated and the common and internal carotid arteries were temporarily clamped while a No. 4-0 nylon suture was passed from the external carotid to the internal carotid artery. The clamp on the common carotid artery was removed and the nylon suture was passed distally, by a premeasured amount, to reach the origin of the middle cerebral artery (MCA). Reperfusion was achieved by removal of the intravascular suture (performed after an MCA occlusion of 2 hours in this study).
Immunohistochemical Studies
Three to six animals were killed at various time points during reperfusion after a 2-hour MCA occlusion: 0, 1, 2, 4, 6, 24, 48, 72, 96, and 168 hours. After anesthesia had been induced with ketamine and xylazine, the rats were killed by transaortic cannulation and perfusion with saline followed by a formalin solution. The brains were extracted and formalin fixed. The fixed brain specimens were sliced in the coronal plane into seven 2-mm-thick sections, which were labeled A through G, anterior to posterior. The specimens were embedded in paraffin, and 2-m-thick slices from sections C and D were mounted on glass slides. Serial, adjacent slices were stained with hematoxylin and eosin, antibodies to cathepsin B, neurofilament protein (marker for neurons), glial fibrillary acidic protein (GFAP; marker for astrocytes), and myeloperoxidase (marker for neutrophils and monocytes). Samples were double labeled with cathepsin B antibody and lectin (an isolectin B4 marker for microglial cells). For the preparation of monospecific anticathepsin B, immunoglobulin G antisera were raised in New Zealand White male rabbits against a cathepsin B-derived synthetic peptide, as described previously. 24, 32 The cathepsin B antibody detects mature and inactive precursor forms of cathepsin B.
Cathepsin B Activity Assay
At designated times of reperfusion after 2 hours of MCA occlusion, a total of 22 rats were killed and their brains were immediately removed. The 4-mm-thick coronal section caudal to the optic chiasm (from +0.2 bregma to Ϫ3.8 bregma) was divided into cortical and subcortical portions, placed into liquid nitrogen, and stored at Ϫ80°C. 30 This region was chosen because the predominant blood supply is from the MCA. 16 Cathepsin B activity was measured by an in vitro fluorometric assay. Activation buffer (10 mM dithiothreitol, 5 mM ethylenediamine tetraacetic acid [EDTA], pH 5.2) was added to the diluted mixture of brain homogenates and buffer (1 mM EDTA, 25 mM (2-[N-morpholino]ethanesulfonic acid, pH 6.5). The substrate (Z-Arg-Arg-NNapOMe) was added in different concentrations and the reaction was allowed to proceed for 30 minutes at 37°C. A stop solution was added and the result was assessed using a fluorophotometer (wavelengths 370/460 nm). Protein determination was performed using the microBCA kit. Cathepsin B enzyme activity was expressed as nanomoles per minute per milligram of protein. The substrate used for the activity assay is highly selective for cathepsin B. 34 All statistical testing was two-sided, assuming an alpha of 0.05. For dependent measures comparing right hemisphere data to left hemisphere data in the same rat, a paired t-test was performed. For statistical analysis of independent samples, such as rats with MCA occlusion compared with sham-operated rats, we used Student's t-test. If the variances were determined to be unequal, we used Welch's t-test instead of Student's t-test.
Intraventricular Infusion Studies
Microosmotic pumps were filled under sterile conditions with either isotonic saline solution (12 animals) or 100 nM stefin A (15 animals). Recombinant stefin A was prepared with an Escherichia coli expression system and then purified using methods described previously. 15 The initial purified solution of stefin A containing 50 mM Na 3 PO 4 neutralized with 1 M HCl was diluted more than 30-fold with isotonic saline. Therefore isotonic saline was chosen as the control solution. The pumps (volume capacity of 100 l) delivered the solutions at a rate of 0.5 l/hour for up to 7 days. After anesthesia had been induced in the rats with halothane, the pumps were implanted subcutaneously in the posterior neck region, with the brain cannula stereotactically placed into the right lateral ventricle and affixed to the skull with liquid adhesive. Body temperature was maintained at a constant temperature of 37°C during surgical procedures. Two to 7 days after pump implantation, dependent on the rats reaching the appropriate weight range, the animals underwent 2 hours of MCA occlusion. The animals were killed after a 7-day reperfusion following the 2-hour MCA occlusion. The brains were formalin fixed and paraffin embedded, and the seven coronal sections, A through G, were sliced 6 m thick and mounted on coated slides. After staining with hematoxylin and eosin, the lesion volume was measured using an image analysis program. The lesion area and the contralateral hemispheric area were calculated by tracing the areas on the computer screen, and the volumes were determined by multiplying the appropriate area by the section interval thickness. 16 The lesion volume is expressed as the percentage of lesion size to the volume of contralateral hemisphere. Statistical analysis was performed using the independent t-test.
Sources of Supplies and Equipment
The Wistar rats were obtained from Charles River Breeding Co. 
Results

Immunohistochemical Studies
Immunohistochemical studies were performed to localize cathepsin B within the brain, specifically within the regions of ischemia. After brief reperfusion and after 2 hours of reperfusion with 2 hours of MCA occlusion, ischemic neurons stained with hematoxylin and eosin in the ipsilateral preoptic region were shrunken or swollen with an intact nucleus. The preoptic region is defined as the ventral subcortical portion of the coronal slice at +0.2 bregma. 30 This region has previously been described as showing early morphological changes of neuronal ischemia after MCA occlusion in the rat and becoming part of the ischemic core. 16 At 2 hours of reperfusion, cortical neurons also demonstrated these ischemic changes. There was dense granular cathepsin B immunoreactivity in the neurons of the preoptic region and cortex compared with the contralateral (left, nonischemic) hemisphere ( Fig. 1 ; 0 hours). The preoptic neurons with increased cathepsin B reactivity coincided with the neurons demonstrating ischemic morphological changes seen in adjacent hematoxylin and eosin-stained sections and ultimately became part of the infarct core. A consistent pattern of diffuse cathepsin B staining was apparent in the extracellular space in the region of the greatest ischemic change and surrounding neuronal necrosis at 2 to 6 hours of reperfusion ( Fig. 1; 2 and 6 hours). Swollen or shrunken neurons with an intact nucleus, consistent with an early or partial ischemic injury, displayed the densest and most granular intracellular cathepsin B-staining pattern. The necrotic "ghost" neurons did not exhibit any intracellular cathepsin B staining, but rather were surrounded by diffuse extracellular staining for cathepsin B. Brain samples obtained from animals after 2 hours of reperfusion were double labeled with lectin (a microglial marker) and cathepsin B antibody (Fig. 2) . There was no significant colocalization of the two stains; that is, increased expression of cathepsin B appeared in affected neurons but not in neighboring microglial cells. By comparing adjacent sections that stained positive for GFAP, astrocytes also had no increase in cathepsin B staining. Penumbral regions such as those bordering the medial cortex did not clearly show the early increase in cathepsin B expression that was seen in the core regions.
By 24 hours of reperfusion after a 2-hour MCA occlusion, cathepsin B staining was no longer seen in neurons in the ipsilateral hemisphere (Fig. 3) . There was diffuse background staining in the infarct core. Neutrophils were infiltrating into the lesion (as demonstrated by myeloperoxidase labeling) by 48 hours after MCA occlusion. These inflammatory cells stained intensely with the cathepsin B antibody ( Fig. 3; 48 hours) . By 96 hours of reperfusion there was a predominance of mononuclear cells infiltrating the core of the infarct ( Fig. 3; 96 hours) . At 168 hours of reperfusion the necrotic ischemic core was filled with cathepsin B-staining inflammatory cells ( Fig. 3; 7 days) .
Cathepsin B Activity
Cathepsin B activity was measured in ischemic brain regions at various times of reperfusion to determine if the enzyme's activity was different from that in control tissue. Consistent with the pattern and temporal profile of increased immunolocalization of cathepsin B, cathepsin B activity was significantly increased in the ischemic hemisphere at 2 hours of reperfusion. At 8 hours of reperfusion after 2 hours of MCA occlusion, cathepsin B activity was significantly increased in the cortex and subcortex of the ischemic hemisphere. By 24 hours of reperfusion no statistical difference in the cathepsin B activity of the ischemic or nonischemic hemisphere was detected. Cathepsin B activity was significantly elevated within the region of infarction at 48 hours of reperfusion (Fig. 4) . When cathepsin B activity in the right hemisphere cortex and subcortex of five sham-operated animals (suture placed in internal carotid artery but not occluding MCA) was compared with that of the left hemisphere in seven animals undergoing a right-sided MCA occlusion, there was no statistical difference in cathepsin B activity (cortex: 
Intraventricular Infusion Studies
Intraventricular infusion of stefin A prior to MCA occlusion was used to test for a protective effect of this enzyme inhibitor on the extent of ischemic cell damage. The percentage of hemispheric infarct volume in 15 animals treated with intraventricular infusion of 0.1 m stefin A (20 Ϯ 3.9% [mean Ϯ SEM]) was significantly reduced (p = 0.025, independent t-test compared with 12 control animals [33 Ϯ 3.5% {mean Ϯ SEM}]). The mean infarct volume was 143 Ϯ 17 mm 3 (mean Ϯ SEM) in the control group and 76 Ϯ 15 mm 3 (mean Ϯ SEM) in the treatment group (p = 0.006; independent t-test). Thus, preischemic intraventricular treatment with stefin A caused a 40% reduction in the volume of cerebral infarction.
Discussion
In this study we have demonstrated that intraventricular infusion of a cysteine protease inhibitor, stefin A, administered before a 2-hour MCA occlusion significantly reduced infarct volume in rats. Cathepsin B, a predominant lysosomal cysteine protease in brain tissue, was expressed in cortical and subcortical neurons by 2 hours of reperfusion after 2 hours of MCA occlusion. There was also increased cathepsin B activity within the ischemic region after 2 hours of reperfusion, although at this early time point the immunolocalization of cathepsin B was restricted to neurons in subportions of the activity assay sample. The cortical and subcortical location of increased expression of cathepsin B within neurons corresponded to regions that subsequently became necrotic with longer reperfusion times. The results of our studies suggest that cathepsin B may play an important role in early neuronal injury after transient focal cerebral ischemia.
Lysosomal proteases have been previously implicated in tissue damage in brain diseases. Transient ischemia in the rat forebrain increases the expression of the aspartic cathepsin D in hippocampus and neostriatum microglia, neurons, and astrocytes. 26 This enzyme contributes to the extent of protein catabolism and the ischemic degenerative response of the affected neurons. Cathepsins B and L have been localized in microglial cells of the normal brain and have been hypothesized to play a critical role in degenerative brain processes. 2 Spontaneously hypertensive rats have progressive ischemic degeneration of the brain with lacunae and cyst formation in the cortical and subcortical regions. Histochemical study showed cathepsin B to be distributed more heavily in the cells in edematous cortex and in degenerating subcortical white matter. 10 Cathepsin B activity in the brain of spontaneously hypertensive rats also increased with advancing age coincident with the progressing extent of the vascular lesions. 10 Immunohistochemical studies in patients diagnosed with early-onset Alzheimer's disease documented increased expression of cathepsins B and D within neurons, suggesting that these enzymes are involved in the degenerative pathological process. 7, 25 In our study the expression of cathepsin B was increased within ischemic neurons, but not in astrocytes or microglial cells, within 2 hours of reperfusion after a 2-hour MCA occlusion. The early peak of cathepsin B activity in the subcortical region corresponded to the increased immunolocalization of cathepsin B within the preoptic neurons at 2 hours of reperfusion. After the first 4 hours of reperfusion, cathepsin B immunoreactivity was reduced in the ischemic neurons, and by 24 hours of reperfusion the affected neurons appeared pale, being devoid of any significant cathepsin B stain.
The increased cathepsin B activity at 48 hours of reperfusion likely reflects the abundance of inflammatory cells infiltrating the ischemic cortical and subcortical regions, as shown in the immunohistochemical analysis to be staining densely with the cathepsin B antibody.
If neuronal cathepsin B is overexpressed and activated within ischemic neurons 2 to 4 hours after onset of focal cerebral ischemia, then perhaps it plays a role in early ischemic neuronal damage by breaking down structural components of the cell. The significant but modest increase in cathepsin B activity at 2 and 8 hours of reperfusion is likely reflective of the use of brain homogenates including a large cellular component other than the ischemic neurons. These affected neurons were the only cells overexpressing cathepsin B at the early time points of reperfusion. Once inflammatory cells infiltrated the infarct by 48 hours of reperfusion, the increase in cathepsin B activity was correspondingly more robust in the ischemic hemisphere. Any therapeutic potential provided by cathepsin B inhibition would likely occur within the first few hours of reperfusion when select neurons are beginning to show signs of cellular injury. To test the potential efficacy of a cathepsin B inhibitor to reduce infarct volume, we infused stefin A into the ipsilateral ventricle prior to the 2-hour MCA occlusion. Animals that received intraventricular stefin A prior to a 2-hour MCA occlusion had a 40% reduction in infarction volume compared with controls (p = 0.025). Because stefin A inhibits other cysteine proteases, the inhibition of cathepsin B may not be exclusively responsible for the beneficial effect seen in this model. Further studies are needed to show the optimum dose-response relationship for stefin A and its effect on infarct volume. In addition, future studies may use inactivated stefin A as a more appropriate control solution to eliminate the possibility of a vehicle-related effect on infarct volume. Evidence for the importance of cathepsin B, however, includes the immunolocalization data as well as its increased activity in the ischemic region. The mechanism of stefin A's beneficial effect is not mediated by the calpain enzyme system, because that cytosolic cysteine protease is insensitive to the inhibitory effects of stefin A. Future experiments designed to investigate the role of the related cathepsins L, S, and H would be warranted.
Cysteine proteases have been implicated as contributing to ischemic cell death in nonneurological conditions. After experimental induction of cardiac and hepatic ischemia, cysteine proteases were released from the injured cells and postulated to contribute to tissue necrosis. 5,12-14, 16,21,28,29 Following systemic shock in humans, cathepsin B activity increased in the circulating blood and its levels correlated with the extent of tissue injury. 17 This latter finding was believed to be secondary to the cathepsin B that is released from circulating white blood cells where they are found in high concentrations. This raises a question concerning the effect of the very early inflammatory cell response on the level of active brain cathepsin B after cerebral ischemia. It is known that white cells are stimulated to adhere to the endothelial surface within hours after cerebral ischemia and that inhibition of this interaction may be protective. 1, 9, 11, 22, 41, 42 Endothelial cells are known to contain cathepsin B. 23 The possibility exists that cathepsin B may contribute to the white cell-endothelial cell interaction and that an inhibitor of cathepsin B may have a cerebral protective effect by acting at the site of the blood vessels in the region of cerebral ischemia within the first few hours of reperfusion. The infiltration of white cells into the region of necrosis 2 to 7 days after cerebral infarction brings cathepsin B into the brain parenchyma, but likely it serves to degrade the cellular debris rather than contribute to progressive neuronal cell death. This is the first study to describe the immunohistochemical localization of cathepsin B and to measure its activity after transient focal cerebral ischemia. The data support the hypothesis that cathepsin B plays a role in the postischemic damage of neurons and provide preliminary results of the ability of a cathepsin B inhibitor to reduce ischemic cerebral injury.
